PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 27, 2026Diagnostics6 citationsOpen Access

Metagenomic and Targeted Next-Generation Sequencing in Infectious Disease Diagnostics: Current Applications, Challenges, and Future Perspectives

View Full Paper
RRRong RongYLYuni LongYLYujing Li

Key Points

  • The research aims to review the applications, challenges, and future perspectives of metagenomic and targeted NGS in infectious disease diagnostics.
  • Comprehensive review of current applications in clinical microbiology
  • Examination of diagnostic performance metrics
  • Discussion of challenges in sensitivity, specificity, and standardization
  • Exploration of integration with public health strategies
  • Metagenomic and targeted NGS significantly improve pathogen detection and resistance profiling.
  • Challenges include bioinformatic complexity and cost-effectiveness.
  • Future opportunities include wastewater epidemiology for monitoring infections.

Abstract

Metagenomic and targeted next-generation sequencing (NGS) technologies are rapidly transforming diagnosis and management for infectious diseases. This review comprehensively examines the current applications of metagenomic NGS (mNGS) and targeted NGS (tNGS) in clinical microbiology, highlighting their roles in pathogen detection, antimicrobial resistance profiling, virulence characterization, and outbreak investigation—particularly in complex cases such as pneumonia, critical illness with pulmonary infections, and pediatric acute respiratory illnesses. We discuss the diagnostic performance, advantages, and limitations of these approaches, including challenges related to sensitivity, specificity, standardization, bioinformatic complexity, and cost-effectiveness. Furthermore, we explore emerging opportunities for integrating NGS-based surveillance with public health strategies, such as wastewater epidemiology, to monitor healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) at the population level. Finally, we outline key steps needed to translate these powerful genomic tools from research settings into routine clinical and public health practice.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Rong et al. (2026) studied this question.

synapsesocial.com/papers/69c6201515a0a509bde1879bhttps://doi.org/10.3390/diagnostics16070991
Ask AI
Helpful
Bookmark
Share
View Full Paper